Terns Pharmaceuticals, Inc. (TERN) Financial Ratios
7 years of historical data (2018–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
12.18
↑+782% vs avg
5yr avg: 1.38
30Y Low1.1·High1.8
ROE
↑
-29.6%
↓+27% vs avg
5yr avg: -40.5%
30Y Low-131%·High-20%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TERN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Terns Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.6B | $440M | $462M | $367M | $179M | — | — | — |
| Enterprise Value | $4.5B | $280M | $383M | $225M | $131M | — | — | — |
| P/E Ratio → | -47.29 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | 178.65 | — | — | — |
| P/B Ratio | 12.18 | 1.27 | 1.81 | 1.32 | 1.11 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TERN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | 130.95 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
TERN Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -29.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | 100.0% | — | — | — |
| Operating Margin | — | — | — | — | -4986.0% | — | — | — |
| Net Profit Margin | — | — | — | — | -5015.8% | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -29.6% | -29.6% | -33.9% | -27.6% | -43.8% | -67.5% | -131.2% | -20.5% |
| ROA | -28.1% | -28.1% | -32.5% | -26.5% | -38.5% | -50.5% | -121.8% | -19.9% |
| ROIC | -42.2% | -42.2% | -49.5% | -37.6% | -62.7% | -440.2% | -1049.8% | -343.2% |
| ROCE | -33.7% | -33.7% | -38.3% | -28.2% | -43.2% | -83.7% | -132.9% | -21.3% |
TERN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $161M exceeds total debt of $1M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.19 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.46 | -0.31 | -0.51 | -0.30 | -0.90 | -0.67 | -0.95 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
Net cash position: cash ($161M) exceeds total debt ($1M)
TERN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Terns Pharmaceuticals, Inc.'s current ratio of 23.14x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 33.68x to 23.14x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 23.14 | 23.14 | 22.39 | 33.68 | 24.48 | 3.98 | 4.49 | 37.25 |
| Quick Ratio | 23.14 | 23.14 | 22.39 | 33.68 | 24.48 | 3.98 | 4.49 | 37.25 |
| Cash Ratio | 22.89 | 22.89 | 22.06 | 33.43 | 24.34 | 3.28 | 3.97 | 36.58 |
| Asset Turnover | — | — | — | — | 0.01 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
TERN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Terns Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $80M | $71M | $36M | $25M | $25M | $25M | $24M |
Peer Comparison
Compare TERN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TERNYou | $5B | -47.3 | — | — | — | — | -29.6% | -42.2% | — |
 MDGL | $12B | -42.0 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 AKRO | $4B | -14.6 | — | — | — | — | -39.2% | -55.3% | — |
 HIMS | $7B | 52.7 | 44.5 | 93.8 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
 ELVN | $2B | -22.5 | — | — | — | — | -27.0% | -32.8% | — |
 GPCR | $2B | -17.0 | — | — | — | — | -11.9% | -30.3% | — |
 VKTX | $4B | -10.1 | — | — | — | — | -47.3% | -44.4% | — |
 ARWR | $11B | -6486.9 | 91.8 | 70.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 ALDX | $105M | -1.9 | — | — | — | — | -58.5% | -369.4% | — |
 HALO | $8B | 25.9 | 8.5 | 12.1 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 INVA | $2B | 6.8 | 8.0 | 9.8 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See TERN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TERN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TERN vs MDGL
Side-by-side business, growth, and profitability comparison vs Madrigal Pharmaceuticals, Inc..
Start ComparisonTERN — Frequently Asked Questions
Quick answers to the most common questions about buying TERN stock.
What is Terns Pharmaceuticals, Inc.'s P/E ratio?
Terns Pharmaceuticals, Inc.'s current P/E ratio is -47.3x. This places it at the 50th percentile of its historical range.
What is Terns Pharmaceuticals, Inc.'s ROE?
Terns Pharmaceuticals, Inc.'s return on equity (ROE) is -29.6%. The historical average is -50.6%.
Is TERN stock overvalued?
Based on historical data, Terns Pharmaceuticals, Inc. is trading at a P/E of -47.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.